Cancer Progression Mechanisms
Cancer Progression Mechanisms - Related Videos
09:25
Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
0 Views •
Cited by 34 •
2013
Improved understanding of pancreatic cancer biology is critically needed to enable the development of better therapeutic options to treat pancreatic cancer. To address this need, we demonstrate an orthotopic model of pancreatic cancer that permits non-invasive monitoring of cancer progression using in vivo bioluminescence imaging.
03:03
mTOR Signaling and Cancer Progression
0 Views •
2023
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:03
mTOR Signaling and Cancer Progression
0 Views •
2021
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors. The mTOR pathway or the...
03:19
Generating PDOX Mouse Model of Colorectal Cancer: Studying Progression of Colorectal Cancer in a Murine Model
0 Views •
2023
This video describes the protocol for generating a patient-derived orthotopic xenograft colorectal cancer mouse model to study the progression of colorectal cancer cells in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. This murine model helps in understanding primary tumor growth and metastases pattern.
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
0 Views •
Cited by 22 •
2010
Reduced/absent expression of Pms2 and/or ERCC1 in entire crypts is a frequent event within 10 cm on each side of colonic adenocarcinomas, likely the basis of a field defect with high mutability and progression to cancer. Deficiency in Ku86 or CcOI is much less frequent in these field defects.
FAQs
Accumulating mutations can progressively disrupt cell-cycle regulation, apoptosis, and DNA repair. These changes allow abnormal cells to survive, divide despite regulatory restraints, and retain additional alterations that support more aggressive behavior. The cumulative nature of this process helps explain how a previously benign lesion can acquire characteristics associated with malignancy rather than changing through a single event.
Altered signaling pathways can coordinate several cancer-promoting behaviors at once, including continued cell division and resistance to programmed cell death. When these pathways no longer respond appropriately to cellular controls, tumor cells gain a survival and growth advantage. Studying the affected signals therefore helps researchers identify mechanisms that targeted therapies may interrupt.
Changes in cell adhesion can weaken relationships that normally restrict tissue movement, while angiogenesis supplies a tumor with new blood vessels. Interactions with the tumor microenvironment further influence how malignant cells grow and invade surrounding structures. Together, these tissue-level factors help connect local tumor expansion with the conditions required for dissemination to distant organs.
The transition reflects the accumulation of changes that expand a lesion’s capabilities beyond localized growth. Disrupted cell-cycle control and apoptosis can support continued expansion, whereas altered adhesion, angiogenesis, and tissue interactions can enable invasion. Malignancy is therefore associated with a broader set of cellular and tissue-level changes than simple enlargement alone.
Researchers examine changes at genetic, cellular, and tissue levels, then relate them to tumor growth, invasion, immune escape, and spread. This multilevel approach connects mutations and signaling abnormalities with observable changes in tumor behavior. It provides a framework for interpreting how molecular alterations produce tissue-level consequences during disease progression.
Mechanistic studies reveal genetic, signaling, cellular, or tissue changes associated with tumor behavior. When a change consistently reflects a relevant progression process, it may serve as a diagnostic biomarker or help characterize disease status. The value of this approach comes from linking measurable biological features to the mechanisms that shape tumor growth or dissemination.
Features that promote invasion, immune evasion, angiogenesis, or distant spread can provide information about how a tumor may behave. Researchers can use knowledge of these mechanisms to interpret progression-associated changes and support outcome prediction. This context is important because tumors with different biological alterations may differ in their likelihood of continued growth or dissemination.
Once a pathway or cellular process is recognized as supporting tumor growth or dissemination, it can become a potential therapeutic target. Targeted approaches aim to interrupt the relevant mechanism rather than treating progression as a single undifferentiated process. This strategy connects biological research with therapies designed to limit tumor expansion or spread.